KEXING BIOPHARM CO.(SH:688136)2025-01-17 10:10Financial Performance - The company expects to achieve a net profit of approximately 30 million yuan for 2024, a turnaround from a net loss of 190.29 million yuan in the same period last year[3]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be around 33 million yuan, compared to a loss of 201.21 million yuan last year[3]. - Revenue is expected to grow by over 10% compared to the previous year, with overseas sales increasing by over 60% due to the commercialization strategy in the EU market[5][6]. Market Strategy - The company has successfully launched paclitaxel in the EU, significantly enhancing its market presence[5]. - Domestic market revenue is showing steady growth, supported by refined management and targeted marketing strategies[6]. Cost Management - Sales, research and development expenses, and production costs have all decreased compared to the previous year, contributing to improved profitability[6]. Non-Recurring Items - The company received government subsidies and experienced changes in the fair value of its private equity fund holdings, impacting non-recurring gains and losses[6]. Financial Reporting - The financial data provided is preliminary and has not yet been audited by external accountants, which may affect the final reported figures[7][8]. - The company emphasizes the importance of monitoring investment risks related to the preliminary financial data[8].